Wednesday, January 9, 2013

• Alnylam's CEO Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript)at Seeking Alpha (Wed, Jan 9)

Tuesday, January 8, 2013

• Pipeline Update from AlnylamZacks (Tue, Jan 8)

Monday, January 7, 2013

• IPO-bound Zafgen names former Alnylam finance exec as CFOat bizjournals.com (Mon, Jan 7)
• ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online (Mon, Jan 7)

Sunday, January 6, 2013

• Alnylam Provides Key 2013 – 2014 Goals for RNAi Therapeutics PipelineBusiness Wire (Sun, Jan 6)

Thursday, January 3, 2013

• Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)Business Wire (Thu, Jan 3)

Wednesday, January 2, 2013

• Alnylam to Webcast Presentation at 31st Annual J.P. Morgan Healthcare ConferenceBusiness Wire (Wed, Jan 2)
• Biotechs dominate list of top-performing Boston-area stocks in 2012at bizjournals.com (Wed, Jan 2)

Wednesday, December 19, 2012

• When Compared To Isis, Alnylam's Valuation Does Not Make Senseat Seeking Alpha (Wed, Dec 19)

Tuesday, December 18, 2012

• Alnylam Falls Behind The Competitionat Seeking Alpha (Tue, Dec 18)

Thursday, December 13, 2012

• 2 Biotech Stocks To Consider This Week In The Wake Of Trial Dataat Seeking Alpha (Thu, Dec 13)

Wednesday, December 12, 2012

• Alnylam shares rise following analyst upgradeAP (Wed, Dec 12)
• Eli Lilly and Other Healthcare Stocks Making Big Moves on December 12, 2012at Investopedia (Wed, Dec 12)

Monday, December 10, 2012

• Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemophilia and Other Bleeding Disorders at 54th American Society of Hematology (ASH) Annual MeetingBusiness Wire (Mon, Dec 10)

Sunday, December 9, 2012

• Alnylam presents new pre-clinical data on RNAi therapeuticstheflyonthewall.com (Sun, Dec 9)

Saturday, December 8, 2012

• Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemoglobinopathies at 54th American Society of Hematology (ASH) Annual MeetingBusiness Wire (Sat, Dec 8)

Monday, December 3, 2012

• Alnylam Pharmaceuticals' Management Presents at Deutsche Bank 2012 dbAccess BioFEST - Transcriptat Seeking Alpha (Mon, Dec 3)

Tuesday, November 27, 2012

• Alnylam to Webcast Presentation at Deutsche Bank 2012 dbAccess BioFESTBusiness Wire (Tue, Nov 27)

Monday, November 26, 2012

• Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patents from the Tuschl II Patent Estate Broadly Covering RNAi TherapeuticsBusiness Wire (Mon, Nov 26)

Wednesday, November 21, 2012

• Alnylam to Webcast Presentation at Upcoming Investor ConferencesBusiness Wire (Wed, Nov 21)

Monday, November 19, 2012

• Alnylam-Tekmira Settle UpZacks (Mon, Nov 19)
• Alnylam: Further Evidence That The Stock Is Overvaluedat Seeking Alpha (Mon, Nov 19)

Friday, November 16, 2012

• Alnylam Pharmaceuticals' CEO Discusses Restructuring of Relationship with Tekmira (Transcript)at Seeking Alpha (Fri, Nov 16)

Thursday, November 15, 2012

• Tekmira Could Offer Stockholders Huge Rewardsat Seeking Alpha (Thu, Nov 15)
• Alnylam: No Approved Drugs, No Promising Candidates, No Justification For $1 Billion Valuationat Seeking Alpha (Thu, Nov 15)

Add ALNY News to My Yahoo!